Prestige Consumer Healthcare (NYSE:PBH) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research report released on Friday.

PBH has been the topic of several other reports. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. DA Davidson restated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 0.1 %

Prestige Consumer Healthcare stock opened at $76.79 on Friday. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.17 and a beta of 0.51. The stock has a fifty day simple moving average of $80.08 and a two-hundred day simple moving average of $74.83. Prestige Consumer Healthcare has a 12 month low of $60.00 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.07 EPS. Equities analysts predict that Prestige Consumer Healthcare will post 4.46 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after buying an additional 433 shares in the last quarter. nVerses Capital LLC raised its holdings in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the last quarter. Huntington National Bank boosted its stake in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares during the last quarter. International Assets Investment Management LLC boosted its position in Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after purchasing an additional 1,138 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Prestige Consumer Healthcare by 49.9% during the third quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after buying an additional 387 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.